SHIRE PLC (NASDAQ:SHPG) Files An 8-K Regulation FD Disclosure

SHIRE PLC (NASDAQ:SHPG) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On April 16, 2018, Shire plc (“Shire”) issued the press release attached as Exhibit 99.1 hereto. The information in the press release is incorporated by reference herein.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. In addition, Exhibit 99.1 contains statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.

Although Shire, as a foreign private issuer, is not subject to Regulation FD, Shire has elected to furnish voluntarily the information herein under Item 7.01.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1Press Release dated April 16, 2018

Shire plc Exhibit
EX-99.1 2 dp89589_ex9901.htm EXHIBIT 99.1 Exhibit 99.1   Press Release     Shire Announces Sale of Oncology Business to Servier for $2.4 Billion   ·Sale of Oncology business unlocks embedded value within Shire’s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases   ·Oncology business provides Servier S.A.S. with an immediate presence in the U.S.,…
To view the full exhibit click here


Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

An ad to help with our costs